Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease

European Neurology

Volumn 42, Issue 3, 1999, Pages 136-140

  Gentil, Michèle ^a   Tournier, Claire Lise ^a   Pollak, Pierre ^a   Benabid, Alim Louis ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Force; Oral control; Parkinson's disease; Speech; STN stimulation

Indexed keywords

DECARBOXYLASE INHIBITOR; LEVODOPA;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; ELECTROSTIMULATION THERAPY; HUMAN; JAW MOVEMENT; LOWER LIP; MALE; MOTOR DYSFUNCTION; MOUTH; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; SPEECH; SPEECH INTELLIGIBILITY; SUBTHALAMIC NUCLEUS; TONGUE; UPPER LIP;

ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; ARTICULATION DISORDERS; DOPAMINE AGENTS; ELECTRIC STIMULATION THERAPY; ELECTRODES, IMPLANTED; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; LIP; MALE; MIDDLE AGED; PARKINSON DISEASE; PULSE THERAPY, DRUG; REACTION TIME; SUBTHALAMIC NUCLEUS; TONGUE; TREATMENT OUTCOME;

EID: 0032872652     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000008087     Document Type: Article

References (16)

1. Marsden CD, Parkes JD: On-off effects in patients with Parkinson's disease on chronic levadopa therapy. Lancet 1976;i:292-296.
2. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, Perret JE, Benabid AL: Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995;345:91-95.
3. Pollak P, Benabid AL, Limousin P, Benazzouz A, Hoffmann D, Le Bas JF, Perret JE: Subthalamic nucleus stimulation alleviates akinesia and rigidity in parkinsonian patients; in Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds): Parkinson's Disease. Advances in Neurology. Philadelphia, Lippincott-Raven, 1996, vol 69, pp 591-594.
4. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL: Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998;16:1105-1111.
5. Stein RB: What muscle variables does the central nervous system control? Behav Brain Sci 1982;5:535-578.
6. Barlow SM, Abbs JH: Force transducers for the evaluation of labial, lingual, and mandibular motor impairments. J Speech Hear Res 1983; 26:616-621.
7. Hunker CJ, Abbs JH, Barlow SM: The relationship between parkinsonian rigidity and hypokinesia in the orofacial system: A quantitative analysis. Neurology 1982;32:749-754.
8. Wood M, Hughes J, Hayes KC, Wolfe DL: Reliability of labial closure force measurements in normal subjects and patients with CNS disorders. J Speech Hear Res 1992;35: 252-258.
9. Luschei ES: Development of objective standards of non-speech oral strength and performance: in Moore CA, Yorkston KM, Beukelman DR (eds): Dysarthria and Apraxia of Speech: Perspectives on Management. Baltimore, Brookes, 1991, pp 3-14.
10. McHenry MA, Minton JT, Wilson RL, Post YV: Intelligibility and nonspeech orofacial strength and force control following traumatic brain injury. J Speech Hear Res 1994;37:1271-1283.
11. Schaltenbrand G, Wahren W: Atlas for Stereotaxy of the Human Brain. Stuttgart, Thieme, 1977.
12. Talairach J, David M, Tournoux P, Corredor H, Kvasina T: Atlas d'Anatomie stereotaxique. Paris, Masson, 1957.
13. Fahn S, Elton RL, and members of the UPDRS development Committee: Unified Parkinson's disease rating scale; in Fahn S, Marsden CD, Calnen DB, Goldstein M (eds): Recent Developments in Parkinson's Disease. New Jersey, MacMillan Healthcare Information, 1987, pp 153-164.
14. Brown SHC, Cooke JD: Amplitude and instruction dependent modulation of movement related electromyogram activity in humans. J Physiol (Lond) 1981;316:97-107.
15. Gentil M, Tournier CL, Perrin S, Pollak P: Effects of levodopa on finger and orofacial movements in Parkinson's disease. Prog Neuropsychopharmacol 1998;22:1261-1274.
16. Barlow SM, Rath EM: Maximum voluntary closing forces in the upper and lower lips of humans. J Speech Hear Res 1985;28:373-376.